Special Issue "Current Applications of Patient-Derived Cancer Model"

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Pathology".

Deadline for manuscript submissions: 18 April 2022.

Special Issue Editors

Dr. Tadashi Kondo
E-Mail Website
Guest Editor
Division of Rare Cancer Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan
Interests: rare cancer research; sarcoma; biobank; precision medicine; biomarker development; target discovery; patient-derived cancer model; proteogenomics; proteomics; bioinformatics
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Noriko Gotoh
E-Mail Website
Guest Editor
Division of Cancer Cell Biology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan
Interests: breast cancer; cancer stem-like cells; tumor microenvironment; tumor organoids; patient-derived cancer model
Dr. Yoshitaka Hippo
E-Mail Website
Guest Editor
Division of Molecular Carcinogenesis, Chiba Cancer Center Research Institute, 666-2, Nitona-cho, Chuo-ku, Chiba-city, Chiba 260-8717, Japan
Interests: multi-step carcinogenesis; animal models; genetic engineering; cellular transformation; organoids; preclinical models; patient-derived cells
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue of Cells collects original research and review articles that address recent research and developments related to patient-derived cancer models and their potential application in basic and translational cancer research.

Patient-derived cancer models, which faithfully reproduce the features of original tumors, have been pivotal tools in cancer research for more than a century. These models provide the data that determine our current understanding of cancer biology, including intriguing functions of novel genes and proteins which are aberrantly regulated in tumors. Well-created models reveal the molecular backgrounds of clinically important observations such as invasion, metastasis, and resistance against treatment. Established cancer research using these models has deepened our understanding of and provided novel therapy for cancers, and a considerable number of cancer models are banked and publicly available to researchers. Thus, patient-derived cancer models are undoubtedly the basis of cancer research. On the other hand, the principal of currently popular patient-derived cancer models was created in the mid-1900s, when our understanding of cancer was remarkably limited, and the fundamental ideas for these models have not considerably progressed since then. Moreover, although the predictive utility of patient-derived cancer models has been expected to facilitate clinical trials and realize precision medicine, their practical utility has not yet been established. Therefore, to cultivate innovative discovery, we need to improve upon the presently available models and challenge novel applications by considering modern technologies, clinical questions, current ideas in cancer biology, and the newest omics data.

The aim of this Special Issue is to collect reports concerning advances in patient-derived cancer models to drive researchers and clinicians towards innovative perspectives on basic and translational cancer research.

We look forward to your contributions to this Special Issue.

Dr. Tadashi Kondo
Prof. Dr. Noriko Gotoh
Dr. Yoshitaka Hippo
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • patient-derived cancer models
  • cell line
  • organoid
  • spheroid
  • xenograft
  • preclinical models

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


The CAM Model for CIC-DUX4 Sarcoma and Its Potential Use for Precision Medicine
Cells 2021, 10(10), 2613; https://doi.org/10.3390/cells10102613 - 01 Oct 2021
Viewed by 385
(1) Background: CIC-DUX4 sarcoma is a rare mesenchymal small round cell tumor which belongs to rare cancers that occupy a significant percentage of cancer cases as a whole, despite each being rare. Importantly, each rare cancer type has different features, and thus there [...] Read more.
(1) Background: CIC-DUX4 sarcoma is a rare mesenchymal small round cell tumor which belongs to rare cancers that occupy a significant percentage of cancer cases as a whole, despite each being rare. Importantly, each rare cancer type has different features, and thus there is a need to develop a model that mimics the features of each of these cancers. We evaluated the idea that the chicken chorioallantoic membrane assay (CAM), a convenient and versatile animal model, can be established for the CIC-DUX4 sarcoma. (2) Methods: Patient-derived cell lines of CIC-DUX4 were applied. These cells were transplanted onto the CAM membrane and tumor formation was examined by H&E staining, immunohistochemistry and Western blotting. The CAM tumor was transferred onto a fresh CAM and was also used to form organoids. Retention of the fusion gene was examined. (3) Results: H&E staining as well as molecular characterization demonstrated the formation of the CIC-DUX4 tumor on the CAM membrane. Expression of cyclin D2 and ETV4 was identified. The CAM tumor was transferred to a fresh CAM to form the second-generation CAM tumor. In addition, we were successful in forming tumor organoids using the CAM tumor. Retention of the fusion gene CIC-DUX4 in the CAM, second-generation CAM, and in the CAM-derived organoids was confirmed by RT-PCR. (4) Conclusions: The CAM assay provides a promising model for CIC-DUX4 sarcoma. Full article
(This article belongs to the Special Issue Current Applications of Patient-Derived Cancer Model)
Show Figures

Figure 1

Back to TopTop